Modern Medicine Cases

Top 10 highest, lowest paying states for internal medicineWith so many changing variables these days, it has become even more important to maintain a steady income. Knowing whether or not your salary is amongst the highest, or lowest, in the country comes in handy when attempting to combat these struggles.
Community mourns loss of ophthalmic leader, Roger Steinert, MD
Community mourns loss of ophthalmic leader, Roger Steinert, MDThe ophthalmic community mourns the loss of Roger Steinert, MD, an internationally renowned and respected corneal, cataract, and refractive surgeon. Dr. Steinert passed away on June 6 at the age of 66 after a 2 ½-year battle with glioblastoma. He died peacefully at his home in Colorado, surrounded by his wife, April, and their family.
5 reasons to prescribe toric contact lenses
New concepts in diagnosis and treatmentIn the past decade, several significant advancements have been made in the arena of glaucoma diagnosis. Spectral domain optical coherence tomography (SD-OCT), newer algorithms in trend analysis of visual field studies, and combined visually evoked potential (VEP) and pattern electroretinography (ERG) studies have been the hallmarks of such recent advancements.
Long-term commitment to diabetes prevention increases successSticking with a prevention program for one year increased the likelihood of success
Telehealth program reduced unneeded diabetic retinopathy referralsA Los Angeles-based program eliminated 14,000 unnecessary visits to specialty care professionals and reduced wait times for patients in need.
NICE recommends dexamethasone adalimumab for uveitisThe UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
Access, costs of bevacizumab key factors for DME therapyThe efficacy of intravitreal bevacizumab (Avastin, Genentech) for improving vision in patients with center-involving diabetic macular edema (DME) has been demonstrated in several clinical trials.
Data clearly demonstrates bevacizumab’s inferiority for DMEAll three anti-vascular endothelial growth factor (anti-VEGF) agents that are commercially available have demonstrated efficacy for the treatment of diabetic macular edema (DME). However, it is clear from the results of clinical trials that outcomes with bevacizumab are not as good as those obtained using ranibizumab or aflibercept, according to Jean-François Korobelnik, MD.
Top 10 tips to unlock telehealth’s potential in your practiceWith the advent of new technologies (particularly those enabling real-time video communication), telehealth is becoming an increasingly common means of providing healthcare services.